Core Viewpoint - Junshi Biosciences aims to establish itself as a global innovative pharmaceutical company with a complete industry chain capability from drug discovery to commercialization, focusing on quality and innovation [2][3]. Company Overview - Junshi Biosciences, founded on December 27, 2012, and listed on July 15, 2020, specializes in the research and commercialization of monoclonal antibody drugs and other therapeutic proteins [7]. - The company's main revenue sources include drug sales (90.67%), technology licensing (8.74%), and other services (0.59%) [7]. Product Development - The company has developed a promising drug portfolio, including its core product, Toripalimab, which is the first domestically approved PD-1 monoclonal antibody in China, with 11 approved indications and one supplemental NDA under review [2]. - Toripalimab is also the first innovative biologic drug developed and produced in China to receive FDA approval, with approvals in multiple regions including the US, EU, and Australia [2]. - Junshi's self-developed Tifcemalimab is the first anti-tumor anti-BTLA monoclonal antibody to enter clinical development, currently undergoing two Phase III trials [2]. Vaccine Development - The company's subsidiary, JunTuo Biotech, is developing vaccine-related products, including monkeypox and Zika vaccines, which are currently in the preclinical development stage [3]. - A collaboration has been established with several research institutions and universities to jointly develop a recombinant protein vaccine for monkeypox [3]. Financial Performance - For the period from January to September 2025, Junshi Biosciences reported revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to the parent company was -596 million yuan, reflecting a year-on-year growth of 35.72% [8]. Market Position - As of September 30, 2025, Junshi Biosciences had 35,900 shareholders, with an average of 21,361 circulating shares per person, a decrease of 12.96% from the previous period [8]. - The company is positioned within the pharmaceutical and biotechnology industry, focusing on innovative drugs, precision medicine, and cancer treatment [8].

Core Viewpoint - The Hong Kong stock market for the biopharmaceutical sector is experiencing a surge in IPO activity, with several companies successfully passing hearings and submitting applications, indicating a positive market sentiment and growth potential in the industry [1][5]. Market Performance - Since December, companies like Jiahe Biotech, Hansai Aitai, Mingji Hospital, and Huazhang Biotech have progressed in the IPO process, while others like Hemei Pharmaceuticals and Gaoguang Pharmaceuticals have submitted their applications [1]. - On December 10, Baoji Pharmaceuticals debuted on the Hong Kong stock market, opening 129% higher and closing at HKD 69 per share, with a total market capitalization of HKD 22.493 billion [1]. - In the first three quarters of this year, 28 companies in the domestic healthcare sector went public, a 100% increase year-on-year, with over 40% being innovative drug companies [1]. Future Outlook - The primary market for biopharmaceutical IPOs in Hong Kong is expected to remain strong, with predictions that it will continue to be the preferred listing location for Chinese biotech companies through 2026 [1]. - The Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange have emphasized the importance of maintaining quality standards in IPO applications while encouraging market participation [1]. Innovation and Competition - The evaluation criteria for innovative drug companies are becoming more comprehensive, focusing on core R&D pipeline competitiveness, product commercialization progress, and profitability [3]. - Companies like Junshi Biosciences and Gaoguang Pharmaceuticals are advancing in business development (BD) collaborations, while others like Hemei Pharmaceuticals and Shiyao Innovation are entering commercialization phases [5][7]. Market Dynamics - The global market for Tumor Infiltrating Lymphocyte (TIL) therapy is projected to grow from USD 104 million in 2024 to USD 1.692 billion by 2030, with the first TIL therapy expected to enter the Chinese market around 2027 [5]. - The number of clinical trials for oncology conducted by Chinese companies has reached 39% of the global total, reflecting the competitive landscape in the oncology sector [6]. Financial Performance - Despite advancements, companies like Hemei Pharmaceuticals and Gaoguang Pharmaceuticals are facing profitability challenges, with reported losses of CNY 73 million and CNY 190 million, respectively, for the first half of 2025 [7]. - Shiyao Innovation, focusing on biopharmaceuticals, reported a net loss of CNY 226 million in the first seven months of 2025, highlighting the financial pressures in the sector [9]. A+H Listing Strategy - The trend of A+H dual listing is becoming more common among biopharmaceutical companies, with Shiyao Innovation exemplifying this strategy [9][10]. - Companies are increasingly cautious about market conditions, as seen with Baili Tianheng delaying its H-share IPO due to concerns over market sentiment and pricing [10][11]. Investment Sentiment - Investors are shifting focus from storytelling to data-driven approaches, emphasizing pipeline focus, data differentiation, and cash flow management to enhance company valuations [11].

Group 1 - The central economic work conference emphasizes the implementation of more proactive macro policies to enhance domestic demand and optimize supply, aiming for qualitative and quantitative economic growth in 2026 [1][2] - The focus on domestic demand is reinforced, with a goal to build a strong domestic market, addressing the current issue of insufficient effective demand, as consumer spending in 2023 accounted for only 39.57% of GDP, significantly lower than global and regional averages [2] - The conference highlights the importance of innovation-driven growth, aiming to cultivate new economic drivers, with a focus on sectors like artificial intelligence and semiconductor technology to enhance productivity and address structural challenges [3] Group 2 - The macroeconomic policy is set to be more proactive, with a focus on quality and efficiency, indicating confidence in the resilience of the domestic economy and a reduced need for extraordinary stimulus measures [4] - Fiscal policy is expected to maintain a certain degree of expansion, with a projected fiscal deficit rate between 3.5% and 4% for 2026, emphasizing the integration of existing and new policies to enhance economic governance [5] - A moderately loose monetary policy is anticipated, with expectations for interest rate cuts and reserve requirement ratio reductions to support economic stability and reasonable price recovery [6] Group 3 - The real estate sector is shifting from being an economic engine to a cornerstone of people's livelihoods, with policies aimed at promoting quality housing and new development models [7] - The capital market is expected to maintain a stable upward trend, supported by ongoing reforms in investment and financing, contributing to wealth preservation and economic transformation [8]

Group 1 - The Hong Kong innovative drug sector is experiencing a rebound, with the Hang Seng Innovative Drug Index rising by 1.3%, potentially ending a four-day decline [1] - Notable stocks in the sector include Kangfang Biotech, which rose over 5%, and other companies like Yimeng Biotech, Cloudtop, and Nuocheng Jianhua, which saw increases of over 3% [1] - The Hang Seng Innovative Drug ETF (159316) recorded a trading volume exceeding 500 million yuan, indicating strong investor interest [1] Group 2 - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security announced the implementation of a new "medical insurance directory" and "commercial insurance innovative drug directory" starting January 1, 2026 [1] - The medical insurance directory will add 114 new drugs, including 50 first-class innovative drugs, while the first version of the commercial insurance directory will include 19 drugs, marking a significant advancement in the multi-layered medical insurance system [1] - According to a report by Zhongtai Securities, innovative drugs remain the most important theme in the pharmaceutical sector, with recent price adjustments leading to a more reasonable valuation and increased investment safety margins and return potential [1] Group 3 - The Hang Seng Innovative Drug Index is the first index with a "purity" of 100% focused on innovative drug companies in Hong Kong, and the Hang Seng Innovative Drug ETF (159316) is currently the only product tracking this index [1] - This ETF provides investors with a convenient way to capitalize on investment opportunities within the innovative drug sector [1]

12月12日午后，港股通创新药板块回暖，高弹性港股通创新药ETF（520880）翻红后持续拉升，现涨超 1%，今日有望终结日线4连阴形态。值得关注的是，本周520880迎来"抄底"资金增仓，累计净申购额超 1.3亿元。 成份股方面，权重龙头股康方生物领涨逾6.8%，信达生物涨超2%，百济神州涨逾1%。云顶新耀、同源 康医药-B、映恩生物-B等涨幅居前。 据康方生物官微消息，其全球首创的PD-1/CTLA-4双特异性抗体卡度尼利单抗联合化疗，对比化疗联 合或不联合纳武利尤单抗，用于HER2阴性、未经治疗的不可切除或转移性胃或胃食管结合部腺癌一线 治疗的国际多中心Ⅲ期临床研究(COMPASSION-37/AK104-311)，已获得美国食品药品监督管理局 (FDA)批准开展。 平安证券研报提示，从BD、商业化、政策三个角度看，创新药崛起具备持续性，建议关注：1）管线布 局丰富的创新药公司；2）创新药单品潜力大，价格有望重估的企业；3）看好前沿技术平台布局领先的 企业。 1、纯粹，全面。不含CXO，纯正创新药！全面覆盖创新药研发类公司。 2、龙头占比大。前十大创新药龙头权重超72%，表征创新药硬核力量。 3、风险更 ...

Core Insights - The pharmaceutical industry is currently experiencing a new wave of innovation, transitioning from small molecule drugs to advanced therapies such as monoclonal antibodies, antibody-drug conjugates (ADCs), small nucleic acid drugs, and cell therapies, which offer more precise targeting and improved patient compliance [4][5][6]. Group 1: Innovation Trends - The global pharmaceutical industry is focusing on five key innovation directions, including the development of GLP-1 drugs for obesity, which are projected to generate approximately $51.8 billion in sales by 2024, reflecting a year-on-year growth of 42%-46% [6]. - ADCs are showing promise in replacing traditional chemotherapy for breast cancer and urothelial carcinoma, with expected sales of around $13 billion in 2024, a 25% increase from previous years [6][7]. - PD-1 monoclonal antibodies are recognized as a cornerstone in cancer immunotherapy, with projected sales exceeding $50 billion in 2024, marking a growth of over 10% [7]. - The prevalence of autoimmune diseases has increased from approximately 7.7% in 2000-2002 to about 11% in 2017-2019, indicating a growing market for innovative treatments targeting these conditions [8]. - Small nucleic acid drugs are expanding from rare genetic diseases to chronic conditions, with a peak sales estimate of around $3 billion for the siRNA drug Leqvio, approved in 2021 [8]. Group 2: China's Pharmaceutical Landscape - China's pharmaceutical industry has rapidly evolved over the past decade, with significant reforms initiated in 2015 that aligned the drug approval process with international standards, facilitating the approval of innovative drugs [9][10]. - The "engineer dividend" in China has led to a surge in talent across all segments of the pharmaceutical industry, enhancing the efficiency and cost-effectiveness of drug development and production [10][11]. - Despite a late start, China's innovative drug sector is experiencing remarkable growth, with a rising share of the global market, currently estimated at 3%-5% compared to a population share of about 18% [15][16]. - Recent government policies are aimed at supporting the development of innovative drugs, with comprehensive measures to enhance research funding, market access, and clinical application [19][20]. Group 3: Investment Strategies - The valuation of innovative drug companies typically employs a pipeline DCF (Discounted Cash Flow) approach, focusing on late-stage or highly probable products, while also considering the lifecycle of drugs and their patent protection [21][22]. - An alternative valuation method based on peak sales (PS) is gaining traction, allowing for a more straightforward assessment of potential revenue based on market consensus [22]. - Investment strategies emphasize the importance of established pharmaceutical companies with strong R&D capabilities and product pipelines, as well as biotech firms with high-potential single products targeting unmet clinical needs [27][28].

中经记者 晏国文 卢志坤 北京报道 （安科生物执行总裁姚建平作主题演讲。） 2025年12月10日，由《中国经营报》主办的"大重构 大机遇"2025中国医药大健康产业论坛在北京隆重 召开。 在会上，安科生物（300009.SZ）执行总裁姚建平以"创新引领企业高质量发展"为主题进行了演讲。姚 建平介绍，经过多年的发展，安科生物已经形成了以生物医药为主轴，以中西药物、精准医疗为两翼， 同时积极布局mRNA技术、ADC、溶瘤病毒、细胞治疗、基因治疗等领域，形成了"一主两翼"协同发展 的战略布局。 "百亿安科，百年安科"是安科生物的战略发展目标。姚建平介绍，"百亿"有三个含义：市值百亿元、营 收百亿元、利润百亿元。 据了解，安科生物是中国最早的生物制药公司之一，是2009年首批在创业板上市的公司之一。 在演讲中，姚建平还提到AI与医药研发的结合。"AI+生物技术、生物医药怎么去结合？其实是完全可 以结合的，比如在药物的大分子设计、药物临床前研究的方案设计、临床研究过程中，包括整个临床方 案的推动……都可以用大数据做一些支撑。一个多肽分子或者一个生物大分子，通过AI来设计，可以 大大缩短它的发现时间，可能会从原来的5年 ...

12月12日午后，港股通创新药板块回暖，高弹性港股通创新药ETF（520880）翻红后持续拉升，现涨超 1%，今日有望终结日线4连阴形态。值得关注的是，本周520880迎来"抄底"资金增仓，累计净申购额超 1.3亿元。 | 分时 多日 1分 5分 * | | | | F9 盘前盘后 图加 九50 图线 工具 @ (2 > | | | | | 港股通创新药ETF ① | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 0.54 | | | 520880[種設通创新的ETF] 14:29 价 0.544 滚球 0.006(1.12%) | | | | 0.544 +0.006 +1.12% | | | 520880 | | 0.543 | | | | | DATES | | SSE CNY 14:29:30 交易中 查看L2全国 | | | 40 8 7 8 | | | | | | | | 净值击势 | 华宜恒生港胶通创新的用 | | 69.80 | | | 0.54 | | | | | 0.45 | 1248 | - ...

Group 1 - The article discusses various ETFs tracking the Sci-Tech Innovation Board indices, highlighting their low fee rates and focus on high-quality stocks in the technology sector [2] - The Sci-Tech Innovation Board 50 ETF tracks the top 50 stocks with significant market capitalization and liquidity, predominantly in the semiconductor sector, which accounts for over 65% of the index [2] - The rolling price-to-earnings (P/E) ratio for the Sci-Tech Innovation Board 50 ETF is reported at 149.8 times, indicating a high valuation relative to earnings [2] Group 2 - The Sci-Tech Innovation Board 100 ETF focuses on 100 medium-cap stocks with good liquidity, primarily in the electronics, biopharmaceuticals, and electrical equipment sectors, which together represent over 80% of the index [2] - The rolling P/E ratio for the Sci-Tech Innovation Board 100 ETF is noted at 210.6 times, reflecting a premium valuation in the market [2] - The Sci-Tech Comprehensive Index ETF covers all market securities on the Sci-Tech Innovation Board, focusing on key industries such as artificial intelligence, semiconductors, and new energy, with a rolling P/E ratio of 204.7 times [2]

天风证券今年8月发布的研报指出，预计普拉替尼纳入医保后有望加速放量。基石药业的临床前管线包 括多特异性抗体、ADC等超过九个潜在候选药物，专注于FIC/BIC研究，涵盖肿瘤学、自身免疫和炎症 性疾病等多个治疗领域。公司创新的内部ADC技术平台，以优化专有连接子为特色，改善肿瘤选择性 有效载荷的释放。平台支持管线2.0多个ADC产品，有望为公司未来发展提供持续动力。 本文源自：智通财经网 消息面上，基石药业近日宣布，公司RET抑制剂普吉华®（普拉替尼胶囊，100 mg）被成功纳入中国国 家医疗保障局公布的最新版《国家基本医疗保险、生育保险和工伤保险药品目录》，该目录将于2026年 1月1日起正式实施。截至目前，基石药业已成功推进4款创新药获批上市，其中3款由基石药业在中国完 成临床试验及注册获批上市的产品，已被纳入国家医保目录。 智通财经获悉，基石药业-B(02616)涨超5%，截至发稿，涨5.57%，报6.07港元，成交额2270.42万港 元。 ...